专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010042701A3 CORTICOSTEROID COMPOSITIONS FOR USE IN TREATING DISEASES OF THE UPPER AND LOWER AIRWAY PASSAGES 审中-公开
标题翻译：用于治疗上下游通气疾病的角质层组合物
公开(公告)号：WO2010042701A3
公开(公告)日：2011-02-17
申请号：PCT/US2009059970
申请日：2009-10-08
申请人： SCHERING CORP , WAN JIANSHENG , MONTEITH DAVID , GUPTA PRANAV , SHAH SAMIR ANUPAM , BERGER ROBERT L , SEQUEIRA JOEL
发明人： WAN JIANSHENG , MONTEITH DAVID , GUPTA PRANAV , SHAH SAMIR ANUPAM , BERGER ROBERT L , SEQUEIRA JOEL
IPC分类号： A61K9/00 , A61K9/107 , A61K31/58 , A61K47/48 , A61P11/02
CPC分类号： A61K9/0043 , A61K9/0078 , A61K9/008 , A61K9/1075 , A61K31/58 , A61K47/6951 , B82Y5/00
摘要： This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages.
摘要翻译：本发明涉及用于制备用于治疗上，下气道通道疾病的药物和药物产品的甾体溶液。本发明的各种实施方案提供了组合物，组合物和剂型，其具有溶解状态的糠酸莫米他松，其适于吸入并且可用于治疗上部和/或下部气道通道的疾病。

2. 发明申请

WO2008073282A3 PH SENSITIVE MATRIX FORMULATION 审中-公开
标题翻译：敏感矩阵公式
公开(公告)号：WO2008073282A3
公开(公告)日：2008-10-02
申请号：PCT/US2007025025
申请日：2007-12-06
申请人： SCHERING CORP , WAN JIANSHENG , CHEN XIAOMING , GUPTA PRANAV , MONTEITH DAVID
发明人： WAN JIANSHENG , CHEN XIAOMING , GUPTA PRANAV , MONTEITH DAVID
IPC分类号： A61K9/20 , A61K31/155
CPC分类号： A61K31/155 , A61K9/0065 , A61K9/2027 , A61K9/2054 , A61K9/2077
摘要： The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH sensitive polymers that are designed for accelerated hydration, expansion, disintegration and dissolution at the higher pH of the upper GI tract, thereby, ensuring that any therapeutic agent that has not been released in the stomach is released in the upper GI tract, thus maximizing absorption of therapeutic agent that has a window of absorption located at the upper GI tract.
摘要翻译：本发明提供了治疗剂的制剂，其受益于在胃和上消化道（GI）道中的延长的受控释放时间，以及增强的药物暴露于上GI道。本发明的制剂包含治疗剂和一种或多种pH敏感聚合物，其被设计用于在上GI道的较高pH下加速水合，膨胀，崩解和溶解，由此确保任何尚未释放的治疗剂胃部在胃肠道上部被释放，从而最大限度地吸收位于胃肠道上部的具有吸收窗口的治疗剂。

3. 发明申请

WO2007143158A3 SUSTAINED RELEASE PHARMACEUTICAL FORMULATION COMPRISING PHENYLEPHRINE 审中-公开
标题翻译：持续释放包含苯乙烯的药物制剂
公开(公告)号：WO2007143158A3
公开(公告)日：2008-11-27
申请号：PCT/US2007013050
申请日：2007-06-01
申请人： SCHERING PLOUGH HEALTHCARE , MONTEITH DAVID , O'MULLANE JOHN , REO JOSEPH P , NOWAK ROBERT T , WAN JIANSHENG , KABIR MOHAMMED A , ABUTARIF MALAZ A , FRITZ GLENN E
发明人： MONTEITH DAVID , O'MULLANE JOHN , REO JOSEPH P , NOWAK ROBERT T , WAN JIANSHENG , KABIR MOHAMMED A , ABUTARIF MALAZ A , FRITZ GLENN E
IPC分类号： A61K9/22 , A61K9/36 , A61K31/137
CPC分类号： A61K31/137 , A61K9/167 , A61K9/2054 , A61K9/209 , A61K9/5026 , A61K9/5042 , A61K31/4545 , A61K47/12 , A61K47/38
摘要： The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.
摘要翻译：本发明公开了一种药物组合物，其包含去氧肾上腺素或其药学上可接受的盐和用于口服给药的可溶性层，其中所述组合物通过在结肠中的吸收递送苯肾上腺素或其药学上可接受的盐。药物组合物包含包含去氧肾上腺素或其药学上可接受的盐的核心和可溶性层，其处于时间依赖性，依赖于pH或结肠特异性的酶依赖性可溶解层，其降解以暴露核心以释放出去氧肾上腺素结肠。在一个优选实施例中，可侵蚀层包裹芯。所述组合物任选地还包含可腐蚀层或其它附加层中的去氧肾上腺素。药物组合物还可以包含一种或多种另外的治疗活性剂，其选自抗组胺剂，止痛剂，抗热解剂和非甾体抗炎剂中的一种或多种。本发明还公开了通过结肠施用苯肾上腺素的方法，从而相对于血浆中的总去氧肾上腺素增加了治疗活性的非共轭去氧肾上腺素的生物可利用量。

4. 发明申请

WO2009129300A3 ORAL PHARMACEUTICAL COMPOSITIONS IN A SOLID DISPERSION COMPRISING PREFERABLY POSACONAZOLE AND HPMCAS 审中-公开
标题翻译：包含优选的他康唑和HPMCAS的固体分散体中的口服药物组合物
公开(公告)号：WO2009129300A3
公开(公告)日：2010-02-11
申请号：PCT/US2009040652
申请日：2009-04-15
申请人： SCHERING CORP , FANG LARRY YUN , HARRIS DAVID , KRISHNA GOPAL , MOTON ALLEN E JR , PRESTIPINO RUSSELL C , STEINMAN MARC , WAN JIANSHENG , WASKIN HETTY ANNE
发明人： FANG LARRY YUN , HARRIS DAVID , KRISHNA GOPAL , MOTON ALLEN E JR , PRESTIPINO RUSSELL C , STEINMAN MARC , WAN JIANSHENG , WASKIN HETTY ANNE
IPC分类号： A61K9/16 , A61K31/00
CPC分类号： A61K47/38 , A61K9/14 , A61K9/1652 , A61K31/496
摘要： The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature temperature (Tg) of less than about 1100C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng.hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.
摘要翻译：本申请提供了包含泊沙康唑和聚合物的新型组合物，其中组合物的玻璃化转变温度温度（Tg）小于约110℃。本申请还描述了包含泊沙康唑和堆积密度大于约0.4mg / mL的聚合物的组合物。本申请还描述了当以禁食状态给予患者时，包含泊沙康唑和提供至少约10,000ng.hr/mL的暴露（AUCtf）的聚合物的组合物。本申请还描述了一种制备这些组合物的新方法。优先聚合物是HPMCAS。优选地，组合物是挤出材料。

5. 发明申请

WO2009129301A2 ORAL PHARMACEUTICAL COMPOSITIONS IN A MOLECULAR SOLID DISPERSION 审中-公开
标题翻译：分子固体分散体中的口服药物组合物
公开(公告)号：WO2009129301A2
公开(公告)日：2009-10-22
申请号：PCT/US2009040653
申请日：2009-04-15
申请人： SCHERING CORP , FANG LARRY YUN , HARRIS DAVID , WAN JIANSHENG
发明人： FANG LARRY YUN , HARRIS DAVID , WAN JIANSHENG
IPC分类号： A61K31/4178
CPC分类号： A61K9/1652
摘要： The present invention provides a solid molecularly dispersed composition comprising a poorly water soluble and weakly basic azole antifungal compound and a pH sensitive polymer, pharmaceutical compositions comprising the solid molecularly dispersed composition of the invention and methods of treating and/or preventing a fungal infection in a patient in need thereof comprising orally administering a pharmaceutical composition comprising a composition of the invention to a patient in need thereof.
摘要翻译：本发明提供了一种包含难溶于水和弱碱性唑类抗真菌化合物和pH敏感性聚合物的固体分子分散组合物，其包含本发明的固体分子量分散组合物的药物组合物和治疗和/或预防在本发明中的真菌感染的方法需要的患者包括向有需要的患者口服施用包含本发明组合物的药物组合物。

6. 发明专利

IL283170D0 A process for hydrating cyclophosphamide freeze-dried composition and product thereof 未知
公开(公告)号：IL283170D0
公开(公告)日：2021-06-30
申请号：IL28317021
申请日：2021-05-13
申请人： SINOTHERAPEUTICS INC , ANDORRA PHARMACEUTICALS LLC , YU HONGZHEN , YI ZIQIANG , WAN JIANSHENG , SHENG XIAOXI
发明人： YU HONGZHEN , YI ZIQIANG , WAN JIANSHENG , SHENG XIAOXI
IPC分类号： A61K9/00 , A61K9/19 , A61K31/675 , A61K47/26
摘要： Provided is a process for hydrating Cyclophosphamide freeze-dried compositions and products obtained therefrom.

7. 发明申请

WO2007052125A3 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ONCE DAILY DOSING CONTAINING PREGABALIN, A MATRIX FORMING AGENT AND A SWELLING AGENT 审中-公开
标题翻译：固体口服药物组合物，用于每日含有孕激素，基质形成剂和开裂剂
公开(公告)号：WO2007052125A3
公开(公告)日：2007-09-07
申请号：PCT/IB2006003063
申请日：2006-10-23
申请人： PFIZER PROD INC , BOCKBRADER HOWARD NORMAN , CHO YUN HYUNG , DIAZ SANTIAGO STEVEN , MAHJOUR MAJID , REYNOLDS THOMAS DANIEL , SHAO PUSHPA GANAPATHI , SHAO ZEZHI JESSE , WAN JIANSHENG
发明人： BOCKBRADER HOWARD NORMAN , CHO YUN HYUNG , DIAZ SANTIAGO STEVEN , MAHJOUR MAJID , REYNOLDS THOMAS DANIEL , SHAO PUSHPA GANAPATHI , SHAO ZEZHI JESSE , WAN JIANSHENG
IPC分类号： A61K9/20 , A61K31/197 , A61P25/00
CPC分类号： A61K47/32 , A61K9/0053 , A61K9/0065 , A61K9/141 , A61K9/146 , A61K9/2027 , A61K31/197 , A61K47/34 , A61K2039/542
摘要： A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要翻译：描述了含有普瑞巴林的固体药物组合物。该组合物包括基质形成剂和溶胀剂，并且适合于每日一次的口服给药。示例性的基质形成剂包括聚乙酸乙烯酯和聚乙烯吡咯烷酮的混合物，示例性的溶胀剂包括聚乙烯吡咯烷酮的交联聚合物。

8. 发明专利

BRPI0910627A2 composições de alta densidade contendo posaconazol e formulações compreendendo as mesmas 未知
公开(公告)号：BRPI0910627A2
公开(公告)日：2015-09-22
申请号：BRPI0910627
申请日：2009-04-15
申请人： SCHERING CORP
发明人： MOTON ALLEN E JR , HARRIS DAVID , KRISHNA GOPAL , WASKIN HETTY ANNE , WAN JIANSHENG , FANG LARRY YUN , STEINMAN MARC , PRESTIPINO RUSSELL C
IPC分类号： A61K9/16 , A61K31/00

9. 发明专利

MX2010011295A COMPOSICIONES FARMACEUTICAS ORALES EN UNA DISPERSION SOLIDA QUE COMPRENDEN PREFERIBLEMENTE POSACONAZOL Y ACETATO-SUCCINATO DE HIDROXIPROPILMETILCELULOSA. 未知
公开(公告)号：MX2010011295A
公开(公告)日：2010-11-12
申请号：MX2010011295
申请日：2009-04-15
申请人： SCHERING CORP
发明人： KRISHNA GOPAL , WAN JIANSHENG , FANG LARRY YUN , HARRIS DAVID , MOTON ALLEN E JR , PRESTIPINO RUSSELL C , STEINMAN MARC , WASKIN HETTY ANNE
IPC分类号： A61K9/16 , A61K31/00
摘要： La presente solicitud provee composiciones novedosas que comprenden posaconazol y un polímero en donde la composición tiene una temperatura de transición de vidrio (TV) menor que aproximadamente 110°C; la solicitud también describe composiciones que comprenden posaconazol y un polímero que tiene una densidad volumétrica mayor que aproximadamente 0.4 mg/mI; la solicitud también describe composiciones que comprenden posaconazol y un polímero que proveen una exposición (AUCtf) de por lo menos aproximadamente 10,000 ng.hr/ml cuando se administran a un paciente en un estado en ayunas; la solicitud también describe un procedimiento novedoso para preparar estas composiciones; el polímero preferido es HPMCAS; preferiblemente la composición es un material extruido.

10. 发明专利

CO6311066A2 COMPOSICIONES DE ALTA DENSIDAD QUE CONTIENEN POSACONAZOL Y FORMULACIONES QUE COMPRENDEN LAS MISMAS 未知
公开(公告)号：CO6311066A2
公开(公告)日：2011-08-22
申请号：CO10141841
申请日：2010-11-11
申请人： SCHERING CORP
发明人： FANG LARRY , HARRIS DAVID , KRISHNA GOPAL , MOTON ALLEN , PRESTIPINO RUSSEL , STEINMAN MARC , WAN JIANSHENG , WASKIN HETTY
IPC分类号： A61K9/16
摘要： Es deseable tener una formulación para administración oral la cual proporcione posaconazol a una población de pacientes con una menor variabilidad paciente a paciente en cuestión de biodisponibilidad, proporcionando así parámetros PK consistentes en una población de pacientes a quienes se administre la formulación, por ejemplo un rango observado más estrecho para valores Cmax y AUC en una población de pacientes a quienes se administra una cantidad fija de una formulación. Además, es deseable tener una formulación para administración oral la cual proporcione una biodisponibilidad de posaconazol superior a la disponible a partir de formulaciones anteriores, proporcionando así niveles superiores en plasma determinados a partir de sangre obtenida de un paciente a quien se administra una cantidad dada de posaconazol (denominados también en la presente por conveniencia niveles en plasma ). Además, es deseable tener una formulación para administración oral la cual proporcione un nivel en plasma aceptable de posaconazol cuando se administra a un paciente en ayunas. Se requiere una composición de posaconazol y una formulación farmacéutica que comprenda una composición de posaconazol que sea apropiada para una administración oral en pacientes en ayunas. y la cual proporcione niveles en plasma terapéuticos y exposición de posaconazol suficiente (AUC) para proporcionar un beneficio terapéutico. Adicionalmente, se requiere una formulación farmacéutica para administración oral la cual proporcione posaconazol en una forma que sea esencialmente insoluble cuando pasa a través del ambiente estomacal, ...

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式